Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro

World Journal of Gastroenterology

Volumn 19, Issue 32, 2013, Pages 5326-5333

  Yang, Feng Rui ^a   Fang, Bu Wu ^a   Lou, Jian Shi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Fufang Biejia Ruangan Pill; Hepatic fibrosis; Transforming growth factor Smad signaling

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; CHINESE DRUG; COLCHICINE; COLLAGEN TYPE 4; FUFANG BIEJIA RUANGAN; HYALURONIC ACID; HYDROXYPROLINE; LAMININ; MESSENGER RNA; PROCOLLAGEN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; COLLAGEN TYPE 3; HERBACEOUS AGENT; MADH3 PROTEIN, RAT; TABLET; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BLOOD; CELL LINE; CHEMICALLY INDUCED; CHINESE MEDICINE; DRUG EFFECTS; LIVER; LIVER CELL; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; PATHOLOGY; TABLET; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CARBON TETRACHLORIDE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; COLLAGEN TYPE III; COLLAGEN TYPE IV; DRUGS, CHINESE HERBAL; FEMALE; HEPATOCYTES; HUMANS; HYALURONIC ACID; HYDROXYPROLINE; LAMININ; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MEDICINE, CHINESE TRADITIONAL; PROCOLLAGEN; RATS; RATS, WISTAR; SMAD3 PROTEIN; TABLETS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84883016311     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i32.5326     Document Type: Article

References (26)

1. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant 2006; 6: 12-19 [PMID: 16433751 DOI: 10.1111/j.1600-6143.2005.01143.x]
2. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99 [PMID: 16563223 DOI: 10.1111/j.1582-4934.2006. tb00292.x]
3. Li Z, Dranoff JA, Chan EP, Uemura M, Sévigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007; 46: 1246-1256 [PMID: 17625791 DOI: 10.1002/hep.21792]
4. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 Suppl 1: S79-S84 [PMID: 17567474 DOI: 10.1111/ j.1440-1746.2006.04659.x]
5. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: where are we? World J Gastroenterol 2006; 12: 509-515 [PMID: 16489661]
6. Gong QM, Xiao JC, Zhou XQ. The clinical study of hepatocirrhosis therapy by using of Fu Fang Bie Jia Ruan Gan Pian. Linchuang Gandanbing Zazhi 2006; 22: 196-198
7. Gong ZJ, Zhan RZ. Common special staining methods. Pathological technique. Shanghai: Shanghai Science and Technology Press, 1994: 70
8. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374 [PMID: 1808228 DOI: 10.1016/0168-8278(91)90084-O]
9. Louis H, Le Moine O, Goldman M, Devière J. Modulation of liver injury by interleukin-10. Acta Gastroenterol Belg 2003; 66: 7-14 [PMID: 12812143]
10. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 95-107 [PMID: 15704042]
11. Zhang G, Zhang FC, Wang TC, Liang KH. [The effects of Chinese national medicine of Huoxueruanjian compound on SMAD signal in hepatic stellate cell and its significance]. Zhonghua Gan Zang Bing Zazhi 2004; 12: 213-215 [PMID: 15099469]
12. Tahashi Y, Matsuzaki K, Date M, Yoshida K, Furukawa F, Sugano Y, Matsushita M, Himeno Y, Inagaki Y, Inoue K. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49-61 [PMID: 11786959 DOI: 10.1053/ jhep.2002.30083]
13. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004; 35: 83-92 [PMID: 15265520 DOI: 10.1016/ j.jdermsci.2003.12.006]
14. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-d807 [PMID: 11897555]
15. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693 [PMID: 16212511 DOI: 10.1146/annurev.cellbio. 21.022404.142018]
16. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584 [PMID: 14534577 DOI: 10.1038/nature]
17. Itoh S, ten Dijke P. Negative regulation of TGF-beta receptor/ Smad signal transduction. Curr Opin Cell Biol 2007; 19: 176-184 [PMID: 17317136 DOI: 10.1016/j.ceb.2007.02.015]
18. Runyan CE, Poncelet AC, Schnaper HW. TGF-beta receptor-binding proteins: complex interactions. Cell Signal 2006; 18: 2077-2088 [PMID: 16824734 DOI: 10.1016/ j.cellsig.2006.05.009]
19. Xu L. Regulation of Smad activities. Biochim Biophys Acta 2006; 1759: 503-513 [PMID: 17182123 DOI: 10.1016/ j.bbaexp.2006.11.001]
20. Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, Han Y, Feng XH, Meng A, Chen YG. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 2007; 27: 4488-4499 [PMID: 17438144]
21. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008; 40: 383-408 [PMID: 18061509]
22. Hill CS. Identification of a Smad phosphatase. ACS Chem Biol 2006; 1: 346-348 [PMID: 17163769 DOI: 10.1016/ j.devcel.2006.03.008]
23. Wicks SJ, Grocott T, Haros K, Maillard M, ten Dijke P, Chantry A. Reversible ubiquitination regulates the Smad/ TGF-beta signalling pathway. Biochem Soc Trans 2006; 34: 761-763 [PMID: 17052192]
24. Verrecchia F, Mauviel A. Transforming growth factorbeta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118: 211-215 [PMID: 11841535 DOI: 10.1046/ j.1523-1747.2002.01641.x]
25. Arias M, Lahme B, Van de Leur E, Gressner AM, Weiskirchen R. Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ 2002; 13: 265-273 [PMID: 12114216]
26. Liu P, Hu YY, Ni LQ. [On establishing comparative reference system for syndrome classification study from the thinking characteristics of syndrome differentiation dependent therapy]. Zhongguo Zhong Xi Yi Jie He Zazhi 2006; 26: 451-454 [PMID: 16883917]